Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Enterprise Value (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Enterprise Value for 4 consecutive years, with -$7.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value fell 917.74% to -$7.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$7.7 million, a 917.74% decrease, with the full-year FY2024 number at -$1.1 million, up 60.83% from a year prior.
  • Enterprise Value was -$7.7 million for Q3 2025 at bioAffinity Technologies, down from -$802835.0 in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$400000.0 in Q1 2025 to a low of -$13.5 million in Q3 2022.
  • A 4-year average of -$5.0 million and a median of -$2.8 million in 2023 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: soared 90.32% in 2024, then plummeted 917.74% in 2025.
  • bioAffinity Technologies' Enterprise Value stood at -$11.4 million in 2022, then surged by 75.28% to -$2.8 million in 2023, then surged by 60.83% to -$1.1 million in 2024, then tumbled by 596.65% to -$7.7 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Enterprise Value are -$7.7 million (Q3 2025), -$802835.0 (Q2 2025), and -$400000.0 (Q1 2025).